Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 58

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 58
---
 Combination, Liminatus will become a wholly-owned subsidiary of ParentCo.

<div align='center'>1</div>

TABLE OF CONTENTS

The business address of Liminatus’s principal executive office 6 Centerpointe Dr. #625, La Palma, California 90623.

#### SPAC MERGER SUB, INC.
SPAC Merger Sub, a Delaware corporation, is a direct wholly-owned subsidiary of ParentCo formed on November 23, 2022 to consummate the Business Combination. SPAC Merger Sub owns no material assets and does not operate any business. In the Business Combination, SPAC Merger Sub will merge with and into Iris, with Iris being the surviving entity and wholly-owned subsidiary of ParentCo. After the consummation of the Business Combination, SPAC Merger Sub will cease to exist.

The mailing address of SPAC Merger Sub’s principal executive office is 6 Centerpointe Dr. #625, La Palma, California 90623.

#### LIMINATUS PHARMA MERGER SUB, INC.
Liminatus Merger Sub, a Delaware corporation, is a direct wholly-owned subsidiary of ParentCo formed on November 23, 2022 to consummate the Business Combination. Liminatus Merger Sub owns no material assets and does not operate any business. In the Business Combination, Liminatus Merger Sub will merge with and into Liminatus, with Liminatus being the surviving entity and wholly-owned subsidiary of ParentCo. After the consummation of the Business Combination, Liminatus Merger Sub will cease to exist.

### The Business Combination Agreement
This section describes the material terms of the Business Combination Agreement. The description in this section and elsewhere in this proxy statement/prospectus is qualified in its entirety by reference to the complete text of the Business Combination Agreement, a copy of which is attached as Annex A to this proxy statement/ prospectus and which is incorporated by reference in this proxy statement/prospectus. This summary does not purport to be complete and may not contain all of the information about the Business Combination Agreement that is important to you. You are encouraged to read the Business Combination Agreement carefully and in its entirety. This section is not intended to provide you with any factual information about Iris, SPAC Merger Sub, Liminatus Merger Sub, ParentCo or Liminatus. Such information can be found elsewhere in this proxy statement/prospectus.

The Business Combination Agreement provides that, subject to the conditions described herein,